Researchers reported that inhibition or genetic targeting of interleukin-2–inducible T-cell kinase (ITK) improves the potency and persistence of anti-CD19 CAR‑T cells in preclinical models. The ITK-directed strategy enhanced CD8+ cytotoxicity and remodeled the T-cell signaling state to reduce exhaustion, producing superior tumor control in hematologic malignancy models. The work suggests a translational path to combine ITK modulation with existing CAR‑T manufacturing processes. Developers may test ITK inhibitors or ex vivo gene edits in early-phase trials to evaluate whether the approach raises response rates or durability without amplifying cytokine toxicities.